On the morning of October 30, China's three major A-share indices fell collectively, while the pharmaceutical sector bucked the trend intraday. The Healthcare ETF Huabao (512170) and the Pharma ETF Huabao (562050) both traded higher.
The medical segment showed localized strength, with Haoyuan Pharma rising more than 10%, Andon Health Co., Ltd. (002432) hitting the daily limit up, and heavyweight Tigermed climbing over 5%.
In the choppy market, "pharma dividend" traditional Chinese medicine stocks regained favor, with Buchang Pharma gaining nearly 4%, and Jilin Aodong and Tongrentang rising more than 2%.
Multiple stocks were boosted by their third-quarter reports: Andon Health Co., Ltd. (002432) reported net profit attributable to shareholders of over 5.2 billion yuan for the first three quarters, a year-on-year increase of more than 227%. Haoyuan Pharma saw both revenue and net profit grow by around 30% year-on-year. Tigermed's revenue rose more than 15% year-on-year. Jilin Aodong's net profit attributable to shareholders grew more than 26% year-on-year.
Overall sector performance: The Healthcare ETF Huabao (512170) currently has 47 constituent companies that have disclosed results, of which 42 are profitable and 25 posted positive year-on-year net profit growth. Joinn Laboratories topped the list with net profit up more than 10-fold year-on-year, while Dian Diagnostics, KingMed Diagnostics, and BGI Genomics ranked high with net profit growth of 750%, 569%, and 335%, respectively.
The Pharma ETF Huabao (562050) currently has 41 constituent companies that have disclosed results, of which 39 are profitable and more than half saw positive year-on-year net profit growth. RemeGen currently leads in growth, with revenue up 293% year-on-year in the first three quarters and net profit attributable to shareholders surging 10-fold year-on-year. Hybio Pharmaceutical, Haisco Pharmaceutical, and Huahai Pharmaceutical followed with net profit growth of 512%, 314%, and 179%, respectively.
To capture recovery opportunities in undervalued pharmaceutical assets, investors may consider these tools: Healthcare ETF Huabao (512170) is a flagship healthcare and medical ETF, with assets under management exceeding 24.3 billion yuan as of the third-quarter report. It focuses on medical devices and healthcare services (with over 30% exposure to CXO) while also covering AI healthcare and consumer healthcare. It is also eligible for margin trading and is an ETF Connect target. Off-exchange feeder fund: 012323.
Pharma ETF Huabao (562050) is the only ETF in the entire market tracking a pharmaceutical index, with an exclusive allocation of roughly "70% innovative drugs plus 20% traditional Chinese medicine," combining the high growth of innovative drugs with the high dividends of traditional Chinese medicine. Off-exchange feeder fund: 024986.
[Data source] Public information including the Shanghai-Hong Kong-Shenzhen exchanges, China Securities Index Company, and Hang Seng Indexes Company. Weight data as of September 30, 2026.
[Fund fee rates] ETFs do not charge sales service fees. When investors subscribe or redeem fund shares, the subscription and redemption agency broker may charge a commission of no more than 0.5%, which includes fees charged by the stock exchange, registrar, and other related parties. Please refer to each fund's legal documents for details on fund fee rates.
[Special reminder] The risk rating assessed by the fund manager for the Healthcare ETF Huabao feeder fund is R4-medium-high risk, suitable for aggressive (C4) and above investors. The risk ratings for the Pharma ETF Huabao, its feeder fund, and the Healthcare ETF Huabao are R3-medium risk, suitable for balanced (C3) and above investors.
[Risk disclosure] The index constituent stocks mentioned in this article are for illustration only. Individual stock descriptions do not constitute investment advice in any form and do not represent the holdings or trading actions of any fund managed by the manager. The constituent stocks of the underlying index are adjusted in a timely manner according to the index compilation rules. Any information appearing in this article (including but not limited to individual stocks, comments, forecasts, charts, indicators, theories, and any form of expression) is for reference only, and investors are responsible for any investment decisions they make independently. In addition, any views, analyses, and forecasts in this article do not constitute investment advice of any form to readers, nor do they assume any responsibility for direct or indirect losses caused by the use of this content. Fund investment involves risks, past performance of a fund does not represent its future performance, and the performance of other funds managed by the fund manager does not guarantee the performance of the fund. Fund investment requires caution.
A MACD golden cross signal has formed, and these stocks are performing well.
Comments